Navigation Links
Cell-based alternative to animal testing

European legislation restricts animal testing within the pharmaceutical and cosmetic industries and companies are increasingly looking at alternative systems to ensure that their products are safe to use. Research published in BioMed Central's open access journal BMC Genomics demonstrates that the response of laboratory grown human cells can now be used to classify chemicals as sensitizing, or non-sensitizing, and can even predict the strength of allergic response, so providing an alternative to animal testing.

Allergic contact dermatitis can result in itching and eczema and is often due to repeated exposure to chemicals at work or in everyday life such as machine oil, detergents, soaps, and cosmetics. Unless the source of the sensitizing chemical is found the resulting rashes can be an ongoing source of misery for the sufferer. The 2009, 7th Amendment to the Cosmetic Directive bans testing of cosmetic products and ingredients on animals meaning that there is currently no way of ensuring new products are hypoallergenic.

Researchers from Lund University in Sweden used genome-wide profiling to measure the response of a human myeloid leukemia cell line to known chemicals. From this they defined a 'biomarker signature' of 200 genes, which could accurately discriminate between sensitizing and non-sensitizing chemicals. By comparing this signature with the known action of these chemicals they were also able to use this system to predict sensitizing potency.

Prof Borrebaeck said, "REACH (Registration, Evaluation, and Authorization of Chemicals) regulation requires that all new and existing chemicals within the European Union are tested for safety. The number of chemicals this includes is over 30,000 and is increasing all the time. Our lab-based alternative to animal testing, although in an early stage of production, is faster, out-performs present alternatives, and, because the cells are human in origin, is more relevant. It provides a way of ensuring the continued safety of consumers and users and, by identifying chemicals and products with low immunogenicity, reducing the suffering due to eczema."


Contact: Dr. Hilary Glover
BioMed Central

Related biology technology :

1. Promega and Cellular Dynamics Partner to Validate Stem Cell-Based In Vitro Assays for Predicting Drug-Induced Cardiotoxicity
2. Dont Wait to Innovate: Future Pharmaceuticals Magazine Releases Its Issue on Innovation in IT, Cell-Based Therapy and Supply Chains
3. O2h and Hypoxium Announce an Agreement to Offer Hypoxiums Specialised In Vitro, Cell-Based Oncology Assays via O2hs Biology Affiliate Program
4. Stemgent, CellDesign Sign Co-Exclusive Marketing Agreement on Stem Cell-Based Adipocyte Research Products
5. MultiVu Video Feed: Geron Receives FDA Clearance to Begin Worlds First Human Clinical Trial of Embryonic Stem Cell-Based Therapy
6. MaxCyte Hosts Live Discussion with Industry Experts on the Challenges in Developing Cell-Based Screening Assays for Drug Discovery
7. The MaxCyte STX Scalable Transfection System to be Launched at the SBS Symposium on Cell-Based Assays
8. Reportlinker Adds Enzymes: Sustainable Alternatives with Remarkable Scope
9. Reportlinker Adds Three Alternative Scenarios of the Future In Vitro Diagnostics Market through 2018
10. Qteros Management to Present at Alternative Energy Investment Banking Conferences
11. Penis Extender Device Engineered for Quick, Safe and Effective Alternative to Penis Enlargement Surgery
Post Your Comments:
(Date:11/30/2015)... Md. , Nov. 30, 2015 ... development company committed to the fostering and monetization ... the current and prospective initiatives designed to create ... Chief Executive Officer of Spherix. "Based on published ... future licensees exceeds $50 billion and Spherix will ...
(Date:11/30/2015)... , Nov. 30, 2015  Champions Oncology, Inc. (CSBR), ... services to personalize the development and use of oncology ... Executive Officer, will be presenting at the LD MICRO ... Pacific Standard Time (PST).  The conference, held at the ... Angeles, CA , will feature 200 small/micro-cap companies ...
(Date:11/30/2015)... 30, 2015 TapImmune, Inc. ... of innovative peptide and gene-based immunotherapeutics and vaccines for ... it will be presenting at the 8 th ... at 2.30 PM PT. Dr. John N. Bonfiglio ... be giving the presentation and will join TapImmune management ...
(Date:11/30/2015)... , Nov. 30, 2015  Aytu BioScience, Inc. (OTCQB: ... and related conditions, will present at two upcoming investor ... an interactive real-time virtual conference, to be held December ... Conference, to be held December 2 nd & ... and streamed live via webcast. ...
Breaking Biology Technology:
(Date:11/17/2015)... , November 17, 2015 ... au 19 novembre  2015.  --> Paris ... --> DERMALOG, le leader de l,innovation biométrique, ... la fois passeports et empreintes sur la même surface ... les passeports et l,autre pour les empreintes digitales. Désormais, ...
(Date:11/12/2015)... CAMBRIDGE, Mass. , Nov. 12, 2015 /PRNewswire/ ... Broad Institute of MIT and Harvard for use ... chemical discovery information management tools. The partnership will ... share both biological and chemical research information internally ... tools will be used for managing the Institute,s ...
(Date:11/9/2015)... , Nov. 09, 2015 ... addition of the "Global Law Enforcement ... offering. --> ) has ... Law Enforcement Biometrics Market 2015-2019" report ... and Markets ( ) has announced ...
Breaking Biology News(10 mins):